Gravol and Renflexis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gravol (dimenhydrinate) and Renflexis (infliximab-abda). Common drug interactions include heart rate increased among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Gravol and Renflexis. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Gravol?

Gravol has active ingredients of dimenhydrinate. It is often used in nausea. eHealthMe is studying from 7,192 Gravol users. Check the latest studies of Gravol.

What is Renflexis?

Renflexis has active ingredients of infliximab-abda. eHealthMe is studying from 1,316 Renflexis users. Check the latest studies of Renflexis.



On Jul, 12, 2026

12 people who take Gravol and Renflexis together, and have interactions are studied.

Gravol and Renflexis drug interactions.

What are the common drug interactions of Gravol and Renflexis, by gender? *:

female:

  1. Heart rate increased
  2. Throat irritation
  3. Throat tightness
  4. Diarrhoea
  5. Erythema (redness of the skin)
  6. Flushing (the warm, red condition of human skin)
  7. Pain
  8. Swelling face
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Anxiety

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Erythema (redness of the skin)
  3. Feeling hot
  4. Immunosuppression
  5. Pain
  6. Somnolence (a state of near-sleep, a strong desire for sleep)

What are the common drug interactions of Gravol and Renflexis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Somnolence (a state of near-sleep, a strong desire for sleep)
  2. Heart rate increased
  3. Throat irritation
  4. Throat tightness
  5. Erythema (redness of the skin)
  6. Anxiety
  7. Blood pressure decreased
  8. Chest discomfort
  9. Dizziness
  10. Flushing (the warm, red condition of human skin)

30-39:

  1. Blood pressure fluctuation
  2. Cardiac disorder
  3. Chest discomfort
  4. Dizziness
  5. Hyperhidrosis (abnormally increased sweating)
  6. Pallor
  7. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

40-49:

  1. Abdominal discomfort
  2. Abdominal pain upper
  3. Ankylosing spondylitis (type of arthritis affecting the spine)
  4. Aphonia (inability to produce voice)
  5. Asthenia (weakness)
  6. Asthma
  7. Back pain
  8. Cardiac disorder
  9. Chest discomfort
  10. Chest pain

50-59:

  1. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
  2. Arthralgia (joint pain)
  3. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
  4. Migraine (headache)
  5. Pain
  6. Renal impairment (severely reduced kidney function)
  7. Respiratory rate decreased (less breathing rate/min)
  8. Somnolence (a state of near-sleep, a strong desire for sleep)
  9. Stress
  10. Vulvovaginal mycotic infection (vulvovaginal fungal infection)

60+:

n/a

What are the existing conditions these people have? *

  1. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 8 people, 66.67%
  2. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 3 people, 25.00%
  3. Migraine (headache): 2 people, 16.67%
  4. Hypersensitivity: 2 people, 16.67%
  5. Headache (pain in head): 2 people, 16.67%
  6. Gastric Ulcer (stomach ulcer): 2 people, 16.67%
  7. Birth Control: 2 people, 16.67%
  8. Anaemia (lack of blood): 2 people, 16.67%
  9. Heart Attack: 1 person, 8.33%
  10. Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Gravol and Renflexis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gravol and Renflexis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gravol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Renflexis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gravol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Renflexis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on dimenhydrinate and infliximab-abda (the active ingredients of Gravol and Renflexis, respectively), and Gravol and Renflexis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: